Skip to main content
The Markets by Proactive
Go to Proactive UK
Proactive UK has moved. Proactive’s coverage of London’s small caps continues on proactiveinvestors.com Go there →
Advertisement
The Markets
by Proactive
Proactive UK has moved.
Coverage of London’s small caps continues on proactiveinvestors.com
Go to Proactive UK
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK
Advertisement
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK

Archive

Proactive news headlines: 88 Energy, Gaming Realms, Immupharma, EQTEC and more

Caldonia has had a buy rating reinstated by house broker Liberum after the gold miner quantified the impact of the one-off charges at is Bilboes development in Zimbabwe.

Reassuringly, added Liberum, the group’s 64%-owned Blanket mine has had a strong start to

Read more

Itaconix PLC (AIM:ITX, OTCQB:ITXXF) has been unable to reach satisfactory commercial terms with one of its major existing merchandising customers in North America for supply in 2024, it said in a statement.

As a result, revenues and adjusted EBITDA for both 2024 and 2025 are expected to be below management's previous expectations, though gross profit margins at the detergent ingredient supplier will improve.

Read more

88 Energy Ltd (AIM:88E, ASX:88E, OTC:EEENF) shares raced to a near 30% gain in Tuesday’s early dealing, after the explorer reported the first flows of oil from well testing at Project Phoenix, on Alaska’s North Slope.

The ongoing testing of the Hickory-1 well confirms a new light oil discovery, in the previously untested Upper SFS (USFS) reservoir.

Read more

Gaming Realms PLC (AIM:GMR, OTCQX:PSDMF) posted another set of record numbers in 2023 and forecast more growth in 2023 as new customers and markets come online.

Revenues in 2023 increased by 26% to £23.4m (2022: £18.7m) and driven by a 33% jump in licensing revenue as demand for its Slingo-based online games continues to grow.

Read more

ImmuPharma PLC (AIM:IMM) has embarked on a new strategy to substantially boost the patent lifespan and market value of its P140 technology platform and fortify its position in autoimmune diseases.

The company's lead asset is being developed to treat systemic lupus erythematosus (SLE), with a phase III clinical trial about to begin.

Read more

Advertisement
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK